Publication Information

{'id': 'https://openalex.org/W3198188212', 'doi': 'https://doi.org/10.1212/wnl.0000000000012716', 'title': 'Longer-term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis', 'display_name': 'Longer-term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis', 'publication_year': 2021, 'publication_date': '2021-09-03', 'ids': {'openalex': 'https://openalex.org/W3198188212', 'doi': 'https://doi.org/10.1212/wnl.0000000000012716', 'mag': '3198188212', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/34475129'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.0000000000012716', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'letter', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5068541928', 'display_name': 'E. Ann Yeh', 'orcid': 'https://orcid.org/0000-0002-5393-7417'}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'E. Ann Yeh', 'raw_affiliation_strings': ['Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.'], 'affiliations': [{'raw_affiliation_string': 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': ['https://openalex.org/I165690674']}, {'raw_affiliation_string': 'Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'institution_ids': ['https://openalex.org/I165690674']}, {'raw_affiliation_string': 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5057706417', 'display_name': 'Dennis Bourdette', 'orcid': 'https://orcid.org/0000-0002-1312-8615'}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Dennis Bourdette', 'raw_affiliation_strings': ['Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.'], 'affiliations': [{'raw_affiliation_string': 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': ['https://openalex.org/I165690674']}, {'raw_affiliation_string': 'Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'institution_ids': ['https://openalex.org/I165690674']}, {'raw_affiliation_string': 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': []}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5038373894', 'display_name': 'Heinz Wiendl', 'orcid': 'https://orcid.org/0000-0003-4310-3432'}, 'institutions': [{'id': 'https://openalex.org/I165690674', 'display_name': 'Oregon Health & Science University', 'ror': 'https://ror.org/009avj582', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I165690674']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Heinz Wiendl', 'raw_affiliation_strings': ['Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.'], 'affiliations': [{'raw_affiliation_string': 'From the Department of Pediatrics (Neurology) (E.A.Y.), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto; Department of Neurology (D.B.), Oregon Health & Science University, Portland; and Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': ['https://openalex.org/I165690674']}, {'raw_affiliation_string': 'Department of Neurology with Institute of Translational Neurology (H.W.), University of Muenster, Germany.', 'institution_ids': []}, {'raw_affiliation_string': 'Department of Neurology (D.B.), Oregon Health & Science University, Portland', 'institution_ids': ['https://openalex.org/I165690674']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': None, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 57}, 'biblio': {'volume': '97', 'issue': '16', 'first_page': '751', 'last_page': '753'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10137', 'display_name': 'Multiple Sclerosis Research Studies', 'score': 0.9981, 'subfield': {'id': 'https://openalex.org/subfields/2734', 'display_name': 'Pathology and Forensic Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10137', 'display_name': 'Multiple Sclerosis Research Studies', 'score': 0.9981, 'subfield': {'id': 'https://openalex.org/subfields/2734', 'display_name': 'Pathology and Forensic Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11491', 'display_name': 'CAR-T cell therapy research', 'score': 0.9935, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11016', 'display_name': 'Monoclonal and Polyclonal Antibodies Research', 'score': 0.9872, 'subfield': {'id': 'https://openalex.org/subfields/2741', 'display_name': 'Radiology, Nuclear Medicine and Imaging'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/ocrelizumab', 'display_name': 'Ocrelizumab', 'score': 0.9882634}, {'id': 'https://openalex.org/keywords/natalizumab', 'display_name': 'Natalizumab', 'score': 0.9627414}, {'id': 'https://openalex.org/keywords/relapsing-remitting', 'display_name': 'Relapsing remitting', 'score': 0.46791178}], 'concepts': [{'id': 'https://openalex.org/C2778843634', 'wikidata': 'https://www.wikidata.org/wiki/Q2013780', 'display_name': 'Ocrelizumab', 'level': 4, 'score': 0.9882634}, {'id': 'https://openalex.org/C2781004633', 'wikidata': 'https://www.wikidata.org/wiki/Q386119', 'display_name': 'Natalizumab', 'level': 3, 'score': 0.9627414}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8665441}, {'id': 'https://openalex.org/C2779015954', 'wikidata': 'https://www.wikidata.org/wiki/Q420164', 'display_name': 'Alemtuzumab', 'level': 3, 'score': 0.7915367}, {'id': 'https://openalex.org/C2780640218', 'wikidata': 'https://www.wikidata.org/wiki/Q8277', 'display_name': 'Multiple sclerosis', 'level': 2, 'score': 0.7852118}, {'id': 'https://openalex.org/C3020694758', 'wikidata': 'https://www.wikidata.org/wiki/Q42417392', 'display_name': 'Relapsing remitting', 'level': 3, 'score': 0.46791178}, {'id': 'https://openalex.org/C542903549', 'wikidata': 'https://www.wikidata.org/wiki/Q422248', 'display_name': 'Monoclonal antibody', 'level': 3, 'score': 0.46707347}, {'id': 'https://openalex.org/C2776036978', 'wikidata': 'https://www.wikidata.org/wiki/Q425137', 'display_name': 'Fingolimod', 'level': 3, 'score': 0.45258743}, {'id': 'https://openalex.org/C2779134260', 'wikidata': 'https://www.wikidata.org/wiki/Q12136', 'display_name': 'Disease', 'level': 2, 'score': 0.4351126}, {'id': 'https://openalex.org/C2780644213', 'wikidata': 'https://www.wikidata.org/wiki/Q704930', 'display_name': 'Progressive multifocal leukoencephalopathy', 'level': 3, 'score': 0.43037412}, {'id': 'https://openalex.org/C177713679', 'wikidata': 'https://www.wikidata.org/wiki/Q679690', 'display_name': 'Intensive care medicine', 'level': 1, 'score': 0.3836704}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.36190814}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.3080331}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.27418017}, {'id': 'https://openalex.org/C2780653079', 'wikidata': 'https://www.wikidata.org/wiki/Q412323', 'display_name': 'Rituximab', 'level': 3, 'score': 0.23183307}, {'id': 'https://openalex.org/C159654299', 'wikidata': 'https://www.wikidata.org/wiki/Q79460', 'display_name': 'Antibody', 'level': 2, 'score': 0.122020274}], 'mesh': [{'descriptor_ui': 'D009103', 'descriptor_name': 'Multiple Sclerosis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D020528', 'descriptor_name': 'Multiple Sclerosis, Chronic Progressive', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D061067', 'descriptor_name': 'Antibodies, Monoclonal, Humanized', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D064987', 'descriptor_name': 'Cell- and Tissue-Based Therapy', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009103', 'descriptor_name': 'Multiple Sclerosis', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.0000000000012716', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/34475129', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.68, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 10, 'referenced_works': ['https://openalex.org/W2107317577', 'https://openalex.org/W2561881161', 'https://openalex.org/W2565433170', 'https://openalex.org/W2909653713', 'https://openalex.org/W2926740446', 'https://openalex.org/W3012517977', 'https://openalex.org/W3041092153', 'https://openalex.org/W3092194790', 'https://openalex.org/W3137894405', 'https://openalex.org/W3198774415'], 'related_works': ['https://openalex.org/W3206571000', 'https://openalex.org/W3107840785', 'https://openalex.org/W2343984847', 'https://openalex.org/W2338099154', 'https://openalex.org/W2089587806', 'https://openalex.org/W2088205067', 'https://openalex.org/W2050459059', 'https://openalex.org/W2045946359', 'https://openalex.org/W2044022462', 'https://openalex.org/W2000379621'], 'abstract_inverted_index': {'Treatment': [0], 'options': [1], 'in': [2, 15], 'multiple': [3], 'sclerosis': [4], '(MS)': [5], 'have': [6, 42, 52, 60, 89], 'expanded': [7], 'tremendously,': [8], 'with': [9, 22, 115, 124, 131], '23': [10], 'disease-modifying': [11], 'therapies': [12], '(DMT)': [13], 'approved': [14, 27], 'the': [16, 23, 37, 63, 85, 101], 'United': [17], 'States': [18], 'since': [19], '1993.': [20], 'Along': [21], 'increasing': [24], 'number': [25], 'of': [26, 36, 39, 65, 93, 103, 111, 113, 134], 'MS': [28], 'DMTs,': [29], 'refinements': [30], 'to': [31, 45, 62, 108], 'diagnostic': [32], 'criteria': [33], 'and': [34, 47, 84, 106], 'recognition': [35], 'benefits': [38], 'early': [40], 'treatment': [41, 58], 'led': [43, 107], 'clinicians': [44], 'diagnose': [46], 'treat': [48], 'patients': [49], 'when': [50], 'they': [51], 'a': [53, 96, 121], 'first': [54], 'demyelinating': [55], 'episode.': [56], 'Furthermore,': [57], 'approaches': [59], 'shifted': [61], 'use': [64, 133], 'more': [66], 'powerful,': [67], 'highly': [68], 'efficacious': [69], 'agents,': [70], 'including': [71], 'monoclonal': [72], 'antibodies': [73], '(mAbs),': [74], 'at': [75], 'onset.1': [76], 'The': [77], 'newer': [78], 'therapies,': [79], 'such': [80], 'as': [81], 'natalizumab,': [82], 'alemtuzumab,': [83], 'anti-B-cell': [86], 'mAb': [87], 'ocrelizumab,': [88], 'made': [90], '"no': [91], 'evidence': [92], 'disease': [94], 'activity"': [95], 'realistic': [97], 'therapeutic': [98], 'target,': [99], 'delayed': [100], 'onset': [102], 'progressive': [104], 'disease,': [105], 'improved': [109], 'quality': [110], 'life': [112], 'individuals': [114], 'MS.': [116], 'Yet': [117], 'these': [118, 135], 'agents': [119], 'are': [120], 'double-edged': [122], 'sword:': [123], 'higher': [125], 'efficacy': [126], 'comes': [127], 'potential': [128], 'risks,': [129], 'particularly': [130], 'long-term': [132], 'therapies.2': [136]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3198188212', 'counts_by_year': [], 'updated_date': '2024-12-12T01:46:06.374035', 'created_date': '2021-09-13'}